Strict IGF-1 Control in Acromegaly (I-Con Study)
Latest Information Update: 23 Nov 2021
At a glance
- Drugs Pegvisomant (Primary)
- Indications Acromegaly
- Focus Therapeutic Use
- Acronyms I-Con Study
- 19 Nov 2021 Status changed from active, no longer recruiting to completed.
- 27 Apr 2021 Planned End Date changed from 31 Jan 2021 to 30 Apr 2022.
- 27 Apr 2021 Planned primary completion date changed from 31 Dec 2020 to 31 Dec 2021.